90/014,265PHENOL DERIVATIVE AND PREPARATION METHOD AND USE IN MEDICINE THEREOF9,517,988Closed

Status

Reexamination Certificate Issued

Filed

Feb 18, 2019

Last Updated

Sep 17, 2019

Art Unit

3991

Requester (Patent Owner)Inferred

Sichuan Haisco Pharmaceutical Co. Ltd.

Requested By

Patent Owner

P.O. Law Firm

Crowell

Sector (CPC)

CChemistry & Materials
C07Organic Chemistry
C07CAcyclic Compounds

USPC

568Organic Compounds

Reexam History (29 events)

Sep 18, 2019CCRDYApplication ready for PDX access by participating foreign offices
Sep 17, 2019REEXInput Issue Number and Issue Date for Reexamination
Aug 26, 2019RXPUBSReexam Forwarded to Office of Publications
Aug 14, 2019MRNRCRX - Mail Notice of Intent to Issue a Reexam Certificate
Jul 16, 2019RXLITSRReexam Litigation Search Conducted
Jul 8, 2019RXA...Response after Non-Final Action
May 17, 2019MR.NFRX - Mail Reexam Non-Final Action
Apr 16, 2019NRX.Notice of Reexam Published in Official Gazette
Mar 22, 2019MREXORX - Mail Ex Parte Request for Reexamination Granted
Feb 28, 2019IDSCInformation Disclosure Statement considered
Feb 20, 2019RXLITSRReexam Litigation Search Conducted
Feb 20, 2019MRXNReexamination Formalities Notice Mailed
Feb 20, 2019MRXNReexamination Formalities Notice Mailed
Feb 20, 2019DOCKCase Docketed to Examiner in GAU
Feb 19, 2019SMALApplicant Has Filed a Verified Statement of Small Entity Status in Compliance with 37 CFR 1.27
Feb 19, 2019SMALApplicant Has Filed a Verified Statement of Small Entity Status in Compliance with 37 CFR 1.27
Feb 19, 2019RXTTLRPTTitle Report
Feb 19, 2019RXPCOMCompletion of Preprocessing - Released to Assigned GAU
Feb 19, 2019RXNREQFDNotice of reexamination request filing date
Feb 19, 2019RXNREQAUNotice of assignment of reexamination request
Feb 19, 2019FTFSFITF set to YES - revise initial setting
Feb 19, 2019BIG.Entity Status Set To Undiscounted (Initial Default Setting or Status Change)
Feb 18, 2019WIDSInformation Disclosure Statement (IDS) Filed
Feb 18, 2019RXPA..Change in Power of Attorney (May Include Associate POA)
Feb 18, 2019RXOSUBReceipt of Original Ex Parte Reexam Request
Feb 18, 2019RXO_40Receipt of Orig. Ex Parte Reexam Request Less Than 40 Pages-Rule 1.20(c )(1)
Feb 18, 2019RXIDS.Information Disclosure Statement Filed
Feb 18, 2019RXA.PEPre-Examination Amendment
Feb 18, 2019BIG.Entity Status Set To Undiscounted (Initial Default Setting or Status Change)

Prosecution, PTAB & CAFC

PTAB Proceedings (IPR, PGR, CBM, DER)

None found

Federal Circuit (CAFC)

None found

Terminal Disclaimer

None found

Prosecution History

None found

Maintenance Fees

Grant
Dec 13, 2016
3.5-yr
Jun 13, 2020
Paid May 28, 2020
7.5-yr
Jun 13, 2024
Paid Jun 13, 2024
11.5-yr
Jun 13, 2028
Expiry
Nov 9, 2035

Entity Status

Large Entity

Expires

Nov 9, 2035 (9.6 yr remaining)

Assignments

201620172018201920202021FiledFANGQIONG LIGUOLIANG LIUJIANYU LIUHUADONG LUOXINFENG LUOLINLIN QINLEI RENPENG CHO TANGSONGLIN WANYONGGANG WEISHIXU YISICHUAN HAISCO PHARMACEUTICAL CO., LTD.HAISCO CHENGDU PHARMACEUTICAL TECHNOLOGY CO., LTD.SICHUAN HAISCO PHARMACEUTICAL CO., LTD.HAISCO INNOVATIVE PHARMACEUTICAL PTE. LTD.
AssignmentReel/Frame: 036996/0178Recorded: Nov 9, 2015

From

FANGQIONG LIInventor
Nov 6, 2015
GUOLIANG LIUInventor
Nov 6, 2015
JIANYU LIUInventor
Nov 6, 2015
HUADONG LUOInventor
Nov 6, 2015
XINFENG LUOInventor
Nov 6, 2015
LINLIN QINInventor
Nov 6, 2015
LEI RENInventor
Nov 6, 2015
PENG CHO TANGInventor
Nov 6, 2015
SONGLIN WANInventor
Nov 6, 2015
YONGGANG WEIInventor
Nov 6, 2015
SHIXU YIInventor
Nov 6, 2015

To

SICHUAN HAISCO PHARMACEUTICAL CO., LTD.

AssignmentReel/Frame: 049870/0888Recorded: Jul 26, 2019

From

SICHUAN HAISCO PHARMACEUTICAL CO., LTD.
Jul 26, 2019

To

HAISCO CHENGDU PHARMACEUTICAL TECHNOLOGY CO., LTD.

AssignmentReel/Frame: 053927/0707Recorded: Sep 29, 2020

From

HAISCO CHENGDU PHARMACEUTICAL TECHNOLOGY CO., LTD
Sep 17, 2020

To

SICHUAN HAISCO PHARMACEUTICAL CO., LTD.

AssignmentReel/Frame: 055085/0397Recorded: Jan 29, 2021

From

SICHUAN HAISCO PHARMACEUTICAL CO., LTD.
Jan 12, 2021

To

HAISCO INNOVATIVE PHARMACEUTICAL PTE. LTD.